Globe says buy Theratechnologies for healthy profiGlobe says buy Theratechnologies for healthy profits
2009-06-16 08:23 ET - In the News
The Globe and Mail reports in its Tuesday edition that Theratechnologies gave back eight cents to finish Monday on the Toronto Stock Exchange at $2.47. The Globe's Allan Robinson writes in the Eye On Equities column the stock has a one-year range of $1.05 to $6.85. Loewen Ondaatje McCutcheon analyst Connie Chen says Theratechnologies has provided more early stage information supporting the use of tesamorelin together with HIV anti-viral therapies. The analyst notes Theratechnologies has a North American partner, EMD Merck Serono, and the potential of entering new commercial partnerships in other places. Ms. Chen rates the shares "buy." The Loewen analyst targets the stock at $6. The Globe's Ted Dixon reported on April 13 that Theratechnologies insiders were buying shares as the stock was hitting new lows and were continuing to buy as the stock moved to higher ground. Theratechnologies was then worth $2.65. Ms. Chen rated the shares "buy" in the Eye column on Jan. 15. She targeted the stock at $6. The equity was then worth $1.63. The Eye column reported on Feb. 5, 2008, that Desjardins Securities analyst Maher Yaghi rated the stock "buy" with a $16.50 target price. It was then trading at $9.63.